Clinical Trials Logo

Hepatitis, Chronic clinical trials

View clinical trials related to Hepatitis, Chronic.

Filter by:

NCT ID: NCT04208035 Recruiting - Chronic Hepatitis c Clinical Trials

Hepatitis C Elimination in the Netherlands

CELINE
Start date: September 17, 2018
Phase:
Study type: Observational

The aim of CELINE is to retrieve and re-evaluate lost to follow-up chronic hepatitis C patients in the Netherlands.

NCT ID: NCT04202653 Not yet recruiting - Chronic Hepatitis b Clinical Trials

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)

Neptune
Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of 3 different antiviral treatment.

NCT ID: NCT04201275 Completed - Chronic Hepatitis C Clinical Trials

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects

Start date: December 18, 2019
Phase: Phase 1
Study type: Interventional

The goal of this study is to assess the tolerability, pharmacokinetics and antiviral activity of HEC74647 in HCV treatment naïve subjects with genotypes 1-6.

NCT ID: NCT04198584 Completed - Chronic Hepatitis C Clinical Trials

Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients

VC-CBCS
Start date: April 10, 2020
Phase: N/A
Study type: Interventional

A pilot feasibility study of a small randomized controlled trial (RCT) comparing a video-conferencing cognitive behavioral coping skills (VC-CBCS) group to standard of care (SC) for symptomatic patients previously diagnosed with chronic hepatitis C to evaluate feasibility, patient satisfaction and differences in symptoms, quality of life and liver markers.

NCT ID: NCT04195074 Recruiting - Chronic Hepatitis b Clinical Trials

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of chronic hepatitis b

NCT ID: NCT04189627 Completed - Clinical trials for Hepatitis C Virus (HCV)

A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation

DETI-2
Start date: February 17, 2020
Phase:
Study type: Observational

The objective of this study is to assess the effectiveness of the glecaprevir/pibrentasvir (GLE/PIB) regimen in adolescent participants aged 12 to <18 years of age with chronic hepatitis C (CHC) in clinical practice in the Russian Federation. The study also plans to assess effectiveness of GLE/PIB in subpopulations of interest like co-infected hepatitis C virus (HCV)/human immunodeficiency virus (HIV) adolescents, in various HCV genotype/subgenotype, cirrhotic and non-cirrhotic participants, treatment-experienced (prior treatment with pegylated interferon (pegIFN) or IFN, and/or Ribavirin (RBV) and/or sofosbuvir [PRS]) and treatment-naïve, adolescents who use drugs (PWUD) and non-drug users.

NCT ID: NCT04182321 Completed - Chronic Hepatitis B Clinical Trials

Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B

Start date: March 13, 2020
Phase: N/A
Study type: Interventional

This is a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of metformin as add-on to entecavir therapy in patients with chronic hepatitis B.

NCT ID: NCT04180150 Recruiting - Chronic Hepatitis B Clinical Trials

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

Start date: November 18, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.

NCT ID: NCT04170452 Enrolling by invitation - Liver Biopsy Clinical Trials

Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta

Start date: October 10, 2019
Phase:
Study type: Observational

Study the content of the HBV DNA in liver biopsy in the patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma

NCT ID: NCT04160897 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

Start date: October 22, 2019
Phase:
Study type: Observational

The current first-line treatment for HBV is long-term oral antiviral drugs to inhibit HBV DNA replication. First-line antiviral drugs recommended by the Chinese 2015 Hepatitis B Guidelines include ETV and TDF. This study is based on a real-world clinical cohort to retrospectively analyze the effects of ETV and TDF on the long-term (5-year) incidence of HCC in Chinese patients with chronic hepatitis B with compensated cirrhosis. The results will guide the revision of the Chinese HBV guidelines.